Bolt Biotherapeutics, Inc.
BOLT
$4.28
$0.081.79%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.50M | 7.70M | 5.20M | 4.17M | 3.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.50M | 7.70M | 5.20M | 4.17M | 3.64M |
| Cost of Revenue | 23.61M | 28.22M | 34.95M | 42.20M | 50.13M |
| Gross Profit | -17.11M | -20.52M | -29.75M | -38.03M | -46.50M |
| SG&A Expenses | 12.77M | 13.80M | 14.63M | 15.09M | 16.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.62M | 42.33M | 49.89M | 57.60M | 66.90M |
| Operating Income | -30.12M | -34.63M | -44.70M | -53.44M | -63.26M |
| Income Before Tax | -29.58M | -33.38M | -42.68M | -50.71M | -63.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.58 | -33.38 | -42.68 | -50.71 | -63.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.58M | -33.38M | -42.68M | -50.71M | -63.35M |
| EBIT | -30.12M | -34.63M | -44.70M | -53.44M | -63.26M |
| EBITDA | -29.02M | -33.34M | -43.24M | -51.83M | -61.54M |
| EPS Basic | -16.34 | -17.78 | -22.27 | -26.48 | -33.14 |
| Normalized Basic EPS | -9.67 | -10.58 | -13.51 | -16.14 | -19.13 |
| EPS Diluted | -16.34 | -17.78 | -22.27 | -26.48 | -33.14 |
| Normalized Diluted EPS | -9.67 | -10.58 | -13.51 | -16.14 | -19.13 |
| Average Basic Shares Outstanding | 7.24M | 7.48M | 7.67M | 7.66M | 7.65M |
| Average Diluted Shares Outstanding | 7.24M | 7.48M | 7.67M | 7.66M | 7.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |